Replies to post #6770 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Another Due Diligence trap eh? LOL

Of the 77 small molecules that made the list from over 8000 small molecules - Algernon owns Ifenprodil.

Do you know who owns the other 76 small molecules?

If anyone else owns them, are those small molecules already in position/in the pipeline/repurposed for COVID-19?

I'd bet there are no other compounds on that list of 77 anywhere close to a clinical trial.

As far as I'm concerned the market remains clueless.

Just as the market remains clueless about Algernon's entire drug pipeline.

Even Chris Moreau, CEO, told everyone in the BioPub video, that other career biotech experts could not understand Algernon's repurposed drugs strategy.

Yet, here we go! ASIA & AUSTRALIA

So the question isn't what is the market saying.

The question is what are the scientists saying:

March 19, 2020

www.cnn.com/2020/03/19/us/fastest-supercomputer-coronavirus-scn-trnd/index.html

What's next

The team will run the simulations on Summit again, using a more accurate model of the coronavirus' spike that was published this month.

For all its power, though, Summit can only do so much. It provided the first step in analysis: identifying promising compounds. Experimental studies are required next to prove which chemicals work best.

"Our results don't mean that we have found a cure or treatment for the coronavirus," said Jeremy Smith, director of the University of Tennessee/Oak Ridge National Laboratory Center for Molecular Biophysics, in a statement.

But the findings could inform future studies.

"Only then will we know whether any of them exhibit the characteristics needed to mitigate this virus."

1 Day Later...

March 20, 2020

Algernon Appoints Novotech as CRO For Phase 2 Coronavirus Ifenprodil Trial

www.globenewswire.com/news-release/2020/03/20/2004243/0/en/Algernon-Appoints-Novotech-as-CRO-For-Phase-2-Coronavirus-Ifenprodil-Trial.html

Excerpts

announce today that it has chosen to appoint award winning Novotech as the contract research organization (“CRO”) for a planned physician initiated study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea.

Novotech will be working to assist the investigators of the planned study, including supporting all aspects of the clinical trial. After the trial is approved, the Company will provide full details on the study protocol and timelines.

The Company also wishes to advise that it has retained Novotech to conduct a feasibility study in Australia for a phase 2 sponsor initiated Ifenprodil COVID-19 trial. Novotech has already identified 3 physicians who have indicated their interest to participate. The Company will update the market shortly.

“Novotech was a natural CRO choice for us to help to support this important investigator-led clinical trial,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “Since Ifenprodil is an already approved drug with a known safety history, we look forward to expedited steps that will make it available to patients as soon as possible under the study guidelines.”

Bottom-line

Algernon is ahead of the "Summit" supercomputer's study recommendation(s) by far >`


/////AMG